spacer
home > white papers > High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts - ILC Dover
WHITE PAPERS
logo_ILC_DoverB.jpg

ILC Dover

phone +1 (302) 335-3911
web http://www.doverpac.com
email 1 Moonwalker Road, Frederica, DE 19946, United States

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Elsevier launches solution to accelerate drug discovery through comprehensive prediction and assessment of drug-drug interactions


More info >>


White Papers

Shipping with Active Packaging Containers: Three Pre-flight Decisions that Impact the Success of High-value Global Shipments

World Courier

It is the dead of winter in the northern hemisphere and the height of summer in the southern, with external temperature fluctuations exceeding 50 degrees. Flight delays have added precious days to the transport of your multi-million dollar shipment of blockbuster drug from South East Asia destined for Russia. In France, the roads are closed for days due to a monster snowstorm, with your irreplaceable shipment of investigational drugs stopped somewhere en route between Paris and the clinical trial site. Will all be lost, or can informed choices made before the shipment departs ensure product safety despite unforeseen circumstances?
More info >>


Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement